|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1703.80
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 9.35 | -4.15 | 27.74 | 16.06 | 34.01 | CEPS(Rs) | 21.40 | 7.16 | 38.82 | 27.51 | 43.43 | DPS(Rs) | 4.00 | 4.00 | 6.50 | 6.00 | 5.00 | Book NAV/Share(Rs) | 401.40 | 395.79 | 405.03 | 380.98 | 373.46 | Tax Rate(%) | 19.34 | -16.82 | 22.77 | 30.86 | 34.30 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 8.52 | 1.56 | 17.18 | 16.12 | 23.57 | EBIT Margin(%) | 5.53 | -0.67 | 14.04 | 9.34 | 19.64 | Pre Tax Margin(%) | 4.66 | -1.23 | 13.70 | 8.89 | 19.35 | PAT Margin (%) | 3.76 | -1.43 | 10.58 | 6.15 | 12.71 | Cash Profit Margin (%) | 8.60 | 2.47 | 14.81 | 10.53 | 16.23 | Performance Ratios | | | | | | ROA(%) | 1.89 | -0.85 | 5.92 | 3.60 | 8.02 | ROE(%) | 2.35 | -1.04 | 7.06 | 4.26 | 9.48 | ROCE(%) | 3.30 | -0.47 | 9.19 | 6.39 | 14.44 | Asset Turnover(x) | 0.50 | 0.60 | 0.56 | 0.59 | 0.63 | Sales/Fixed Asset(x) | 1.60 | 2.04 | 2.00 | 2.26 | 2.64 | Working Capital/Sales(x) | 2.87 | 2.69 | 1.69 | 1.43 | 1.62 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.62 | 0.49 | 0.50 | 0.44 | 0.38 | Receivable days | 87.01 | 81.97 | 104.42 | 113.21 | 130.71 | Inventory Days | 99.91 | 81.59 | 79.66 | 73.88 | 67.63 | Payable days | 121.07 | 115.55 | 127.82 | 125.75 | 125.00 | Valuation Parameters | | | | | | PER(x) | 69.32 | 0.00 | 36.80 | 36.72 | 21.73 | PCE(x) | 30.28 | 104.18 | 26.30 | 21.43 | 17.02 | Price/Book(x) | 1.61 | 1.88 | 2.52 | 1.55 | 1.98 | Yield(%) | 0.62 | 0.54 | 0.64 | 1.02 | 0.68 | EV/Net Sales(x) | 2.66 | 2.94 | 4.19 | 2.30 | 2.94 | EV/Core EBITDA(x) | 25.55 | 81.28 | 21.32 | 10.67 | 10.62 | EV/EBIT(x) | 47.94 | -393.30 | 27.74 | 23.00 | 14.04 | EV/CE(x) | 1.32 | 1.55 | 2.12 | 1.23 | 1.70 | M Cap / Sales | 2.62 | 2.88 | 4.19 | 2.42 | 2.94 | Growth Ratio | | | | | | Net Sales Growth(%) | -4.36 | 6.47 | 0.27 | -2.91 | 12.57 | Core EBITDA Growth(%) | 175.48 | -80.39 | -8.80 | -24.21 | 41.82 | EBIT Growth(%) | 810.40 | -105.27 | 51.18 | -53.54 | 30.14 | PAT Growth(%) | 325.34 | -114.99 | 72.99 | -52.72 | 14.44 | EPS Growth(%) | 325.09 | -114.97 | 72.73 | -52.77 | 14.34 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.03 | 0.04 | 0.02 | 0.00 | 0.00 | Current Ratio(x) | 2.09 | 2.38 | 3.72 | 4.24 | 4.75 | Quick Ratio(x) | 1.25 | 1.49 | 2.67 | 3.27 | 3.59 | Interest Cover(x) | 6.35 | -1.20 | 41.12 | 21.01 | 67.04 | Total Debt/Mcap(x) | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 |
|
|
|
|
|
|